FeesSafety
Pluang+

DiagnaMed refiles financials amid shift to natural hydrogen exploration and plans name change to GeoHydrogen.

Company Fundamentals
04 Nov 2026, 14:30 WIB
GlobeNewsWire
View Source
Neutral
DiagnaMed refiles financials amid shift to natural hydrogen exploration and plans name change to GeoHydrogen.

DiagnaMed Holdings Corp. has amended and refiled its annual and interim financial statements following a review by the British Columbia Securities Commission. The revisions clarify the company's transition from AI technology to natural hydrogen exploration and update disclosures on legacy technology and a private placement. The company also plans to change its name to GeoHydrogen Corp. as it focuses on developing clean hydrogen projects in Canada. This refiling aims to ensure regulatory compliance and transparency as the company shifts its business focus.

DiagnaMed Holdings Corp.'s financial refiling provides context for readers. For those following the Energy sector, here is Pluang's market snapshot as of Nov 04, 2026 19:11 WIB: Of 79 priced US Energy stocks, 31 rose and 43 fell. Notable movers include Solaredge Technologies Inc (SEDG) down 15.18% at USD 27.89 with 100% sell order activity, First Solar, Inc. (FSLR) up 6.83% at USD 198.60 with nearly balanced buy/sell orders, and Sunrun Inc (RUN) up 5.18% at USD 9.13 with 58% buy orders. Typical hold times vary from 17 to 77 days among these names.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
27 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
27 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
27 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
27 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
27 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App